Lode Resources may have found more than antimony at Montezuma. What does it mean for ASX:LDR investors?
Read More Pharma Industry News Argent BioPharma (ASX: RGT) acquires AusCann assets in $15m deal — can it unlock U.S. listing potential? Argent BioPharma acquires AusCann assets in a $15M deal to expand its clinical pipeline, strengthen EU infrastructure, and advance toward a U.S. listing. byPallavi MadhirajuAugust 28, 2025